RG
Redmile Group Portfolio holdings
AUM
$940M
This Quarter Return
-7.28%
1 Year Return
+75.78%
3 Year Return
+543.67%
5 Year Return
+585.96%
10 Year Return
+6,653.82%
AUM
$2.1B
AUM Growth
+$2.1B
(-19%)
Cap. Flow
-$445M
Cap. Flow
% of AUM
-21.18%
Top 10 Holdings %
Top 10 Hldgs %
55.38%
Holding
76
New
4
Increased
13
Reduced
27
Closed
8
Top Buys
| 1 |
RYZB
RayzeBio, Inc. Common Stock
RYZB
|
$41.2M |
| 2 |
Boston Scientific
BSX
|
$20.2M |
| 3 |
Biohaven
BHVN
|
$13.5M |
| 4 |
Regenxbio
RGNX
|
$9.01M |
| 5 |
Evolent Health
EVH
|
$6.86M |
Top Sells
| 1 |
Krystal Biotech
KRYS
|
$65.3M |
| 2 |
BioMarin Pharmaceuticals
BMRN
|
$42.4M |
| 3 |
Jazz Pharmaceuticals
JAZZ
|
$42.4M |
| 4 |
Amicus Therapeutics
FOLD
|
$31.9M |
| 5 |
Immunovant
IMVT
|
$31.4M |
Sector Composition
| 1 | Healthcare | 96.1% |
| 2 | Industrials | 3.83% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Kymera Therapeutics
KYMR
$3.1B
| $26M | 1.24% |
1,868,507
| – | – |
|
27
Stryker
SYK
$149B
| $25.9M | 1.23% |
94,738
+8,839
| +10% | +$2.42M |
|
|
IGMS
28
DELISTED
IGM Biosciences
IGMS
| $24.8M | 1.18% |
2,971,542
| – | – |
|
29
DexCom
DXCM
$30.9B
| $22.8M | 1.08% |
244,391
-44,770
| -15% | -$4.18M |
|
30
Nurix Therapeutics
NRIX
$723M
| $22.4M | 1.07% |
2,848,827
-8,482
| -0.3% | -$66.7K |
|
31
Entrada Therapeutics
TRDA
$202M
| $20.3M | 0.97% |
1,284,000
-27,572
| -2% | -$436K |
|
32
Cogent Biosciences
COGT
$1.83B
| $20M | 0.95% |
2,053,333
| – | – |
|
33
Stoke Therapeutics
STOK
$1.08B
| $15.3M | 0.73% |
3,872,696
-82,492
| -2% | -$325K |
|
|
GRTS
34
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
| $14.6M | 0.7% |
8,509,126
+1,648,900
| +24% | +$2.84M |
|
35
Xenon Pharmaceuticals
XENE
$2.99B
| $14.3M | 0.68% |
419,568
-700,908
| -63% | -$23.9M |
|
|
36
Biohaven
BHVN
$1.71B
| $13.5M | 0.64% |
+518,924
| New | +$13.5M |
|
37
Charles River Laboratories
CRL
$7.99B
| $13M | 0.62% |
66,382
-47,969
| -42% | -$9.4M |
|
38
ADC Therapeutics
ADCT
$370M
| $12.7M | 0.61% |
14,178,045
+128,110
| +0.9% | +$115K |
|
|
39
Evolent Health
EVH
$1.11B
| $12.7M | 0.6% |
465,282
+251,850
| +118% | +$6.86M |
|
40
Prime Medicine
PRME
$595M
| $12.6M | 0.6% |
1,324,350
| – | – |
|
41
89bio
ETNB
$1.37B
| $11.8M | 0.56% |
761,955
| – | – |
|
|
VERV
42
DELISTED
Verve Therapeutics
VERV
| $10.7M | 0.51% |
809,777
-252,183
| -24% | -$3.34M |
|
43
Absci
ABSI
$356M
| $10.6M | 0.5% |
8,031,094
| – | – |
|
|
ALLK
44
DELISTED
Allakos
ALLK
| $9.39M | 0.45% |
4,135,061
+1,851,467
| +81% | +$4.2M |
|
45
Atara Biotherapeutics
ATRA
$88.7M
| $9.3M | 0.44% |
6,280,813
+232,690
| +4% | +$344K |
|
46
Stereotaxis
STXS
$246M
| $9.11M | 0.43% |
5,765,792
-608,106
| -10% | -$961K |
|
47
Shattuck Labs
STTK
$61.3M
| $8.54M | 0.41% |
5,619,914
| – | – |
|
48
Annexon
ANNX
$225M
| $8.27M | 0.39% |
3,503,190
| – | – |
|
|
SNCE
49
DELISTED
Science 37 Holdings, Inc. Common Stock
SNCE
| $7.92M | 0.38% |
19,808,234
| – | – |
|
50
RAPT Therapeutics
RAPT
$187M
| $7.1M | 0.34% |
427,490
-4,429
| -1% | -$73.7K |
|